Update your location to show providers, locations, and services closest to you.
Pediatric Endocrinologist (Child Hormone Specialist)
Dr. Haller's research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to…
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
128 publications
2024
Journal of General Internal Medicine
Publisher's site2024
Diabetes Care
PubMed • Publisher's site2024
The Joint Commission Journal on Quality and Patient Safety
Publisher's site2023
Diabetes Care
PubMed • Publisher's site2023
Journal of diabetes science and technology
PubMed • Publisher's site